Skip to main content
Top
Published in: Diagnostic Pathology 1/2012

Open Access 01-12-2012 | Research

Molecular correlates and prognostic significance of SATB1 expression in colorectal cancer

Authors: Björn Nodin, Henrik Johannesson, Sakarias Wangefjord, Darran P O’Connor, Kajsa Ericson Lindquist, Mathias Uhlén, Karin Jirström, Jakob Eberhard

Published in: Diagnostic Pathology | Issue 1/2012

Login to get access

Abstract

Background

Special AT-rich sequence-binding protein 1 (SATB1) is a global gene regulator that has been reported to confer malignant behavior and associate with poor prognosis in several cancer forms. SATB1 expression has been demonstrated to correlate with unfavourable tumour characteristics in rectal cancer, but its association with clinical outcome in colorectal cancer (CRC) remains unclear. In this study, we examined the prognostic impact of SATB1 expression in CRC, and its association with important molecular characteristics; i.e. beta-catenin overexpression, microsatellite instability (MSI) screening status, and SATB2 expression.

Methods

Immunohistochemical expression of SATB1 and beta-catenin was assessed in tissue microarrays with tumours from 529 incident CRC cases in the prospective population-based Malmö Diet and Cancer Study, previously analysed for SATB2 expression and MSI screening status. Spearmans Rho and Chi-Square tests were used to explore correlations between SATB1 expression, clinicopathological and investigative parameters. Kaplan Meier analysis and Cox proportional hazards modelling were used to explore the impact of SATB1 expression on cancer specific survival (CSS) and overall survival (OS).

Results

SATB1 was expressed in 222 (42%) CRC cases and negative, or sparsely expressed, in adjacent colorectal mucosa (n = 16). SATB1 expression was significantly associated with microsatellite stable tumours (p < 0.001), beta-catenin overexpression (p < 0.001) and SATB2 expression (p < 0.001). While not prognostic in the full cohort, SATB1 expression was significantly associated with poor prognosis in SATB2 negative tumours (HR = 2.63; 95% CI 1.46-4.71; pinteraction = 0.011 for CSS and HR = 2.31; 95% CI 1.32-4.04; pinteraction = 0.015 for OS), remaining significant in multivariable analysis.

Conclusions

The results of this study demonstrate that SATB1 expression in CRC is significantly associated with beta-catenin overexpression, microsatellite stability and SATB2 expression. Furthermore, SATB1 expression is a factor of poor prognosis in SATB2 negative tumours. Altogether, these data indicate an important role for SATB1 in colorectal carcinogenesis and suggest prognostically antagonistic effects of SATB1 and SATB2. The mechanistic basis for these observations warrants further study.

Virtual slides

Appendix
Available only for authorised users
Literature
1.
go back to reference Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 2005, 55 (2): 74-108.CrossRefPubMed Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 2005, 55 (2): 74-108.CrossRefPubMed
2.
go back to reference Dobreva G, Dambacher J, Grosschedl R: SUMO modification of a novel MAR-binding protein, SATB2, modulates immunoglobulin mu gene expression. Genes Dev. 2003, 17 (24): 3048-3061.PubMedCentralCrossRefPubMed Dobreva G, Dambacher J, Grosschedl R: SUMO modification of a novel MAR-binding protein, SATB2, modulates immunoglobulin mu gene expression. Genes Dev. 2003, 17 (24): 3048-3061.PubMedCentralCrossRefPubMed
3.
go back to reference Magnusson K, de Wit M, Brennan DJ, Johnson LB, McGee SF, Lundberg E, Naicker K, Klinger R, Kampf C, Asplund A, et al.: SATB2 in combination with cytokeratin 20 identifies over 95% of all colorectal carcinomas. Am J Surg Pathol. 2011, 35 (7): 937-948.CrossRefPubMed Magnusson K, de Wit M, Brennan DJ, Johnson LB, McGee SF, Lundberg E, Naicker K, Klinger R, Kampf C, Asplund A, et al.: SATB2 in combination with cytokeratin 20 identifies over 95% of all colorectal carcinomas. Am J Surg Pathol. 2011, 35 (7): 937-948.CrossRefPubMed
4.
go back to reference Eberhard J, Gaber A, Wangefjord S, Nodin B, Uhlen M, Ericson Lindquist K, Jirstrom K: A cohort study of the prognostic and treatment predictive value of SATB2 expression in colorectal cancer. Br J Cancer. 2012, 106 (5): 931-938.PubMedCentralCrossRefPubMed Eberhard J, Gaber A, Wangefjord S, Nodin B, Uhlen M, Ericson Lindquist K, Jirstrom K: A cohort study of the prognostic and treatment predictive value of SATB2 expression in colorectal cancer. Br J Cancer. 2012, 106 (5): 931-938.PubMedCentralCrossRefPubMed
5.
go back to reference Wang S, Zhou J, Wang XY, Hao JM, Chen JZ, Zhang XM, Jin H, Liu L, Zhang YF, Liu J, et al.: Down-regulated expression of SATB2 is associated with metastasis and poor prognosis in colorectal cancer. J Pathol. 2009, 219 (1): 114-122.CrossRefPubMed Wang S, Zhou J, Wang XY, Hao JM, Chen JZ, Zhang XM, Jin H, Liu L, Zhang YF, Liu J, et al.: Down-regulated expression of SATB2 is associated with metastasis and poor prognosis in colorectal cancer. J Pathol. 2009, 219 (1): 114-122.CrossRefPubMed
6.
go back to reference Alvarez JD, Yasui DH, Niida H, Joh T, Loh DY, Kohwi-Shigematsu T: The MAR-binding protein SATB1 orchestrates temporal and spatial expression of multiple genes during T-cell development. Genes Dev. 2000, 14 (5): 521-535.PubMedCentralPubMed Alvarez JD, Yasui DH, Niida H, Joh T, Loh DY, Kohwi-Shigematsu T: The MAR-binding protein SATB1 orchestrates temporal and spatial expression of multiple genes during T-cell development. Genes Dev. 2000, 14 (5): 521-535.PubMedCentralPubMed
7.
go back to reference Yasui D, Miyano M, Cai S, Varga-Weisz P, Kohwi-Shigematsu T: SATB1 targets chromatin remodelling to regulate genes over long distances. Nature. 2002, 419 (6907): 641-645.CrossRefPubMed Yasui D, Miyano M, Cai S, Varga-Weisz P, Kohwi-Shigematsu T: SATB1 targets chromatin remodelling to regulate genes over long distances. Nature. 2002, 419 (6907): 641-645.CrossRefPubMed
8.
go back to reference Han HJ, Russo J, Kohwi Y, Kohwi-Shigematsu T: SATB1 reprogrammes gene expression to promote breast tumour growth and metastasis. Nature. 2008, 452 (7184): 187-193.CrossRefPubMed Han HJ, Russo J, Kohwi Y, Kohwi-Shigematsu T: SATB1 reprogrammes gene expression to promote breast tumour growth and metastasis. Nature. 2008, 452 (7184): 187-193.CrossRefPubMed
9.
go back to reference Cheng C, Lu X, Wang G, Zheng L, Shu X, Zhu S, Liu K, Wu K, Tong Q: Expression of SATB1 and heparanase in gastric cancer and its relationship to clinicopathologic features. APMIS. 2010, 118 (11): 855-863.CrossRefPubMed Cheng C, Lu X, Wang G, Zheng L, Shu X, Zhu S, Liu K, Wu K, Tong Q: Expression of SATB1 and heparanase in gastric cancer and its relationship to clinicopathologic features. APMIS. 2010, 118 (11): 855-863.CrossRefPubMed
10.
go back to reference Lu X, Cheng C, Zhu S, Yang Y, Zheng L, Wang G, Shu X, Wu K, Liu K, Tong Q: SATB1 is an independent prognostic marker for gastric cancer in a Chinese population. Oncol Rep. 2010, 24 (4): 981-987.PubMed Lu X, Cheng C, Zhu S, Yang Y, Zheng L, Wang G, Shu X, Wu K, Liu K, Tong Q: SATB1 is an independent prognostic marker for gastric cancer in a Chinese population. Oncol Rep. 2010, 24 (4): 981-987.PubMed
11.
go back to reference Tu W, Luo M, Wang Z, Yan W, Xia Y, Deng H, He J, Han P, Tian D: Upregulation of SATB1 promotes tumor growth and metastasis in liver cancer. Liver international: official journal of the International Association for the Study of the Liver. 2012, 32 (7): 1064-1078.CrossRef Tu W, Luo M, Wang Z, Yan W, Xia Y, Deng H, He J, Han P, Tian D: Upregulation of SATB1 promotes tumor growth and metastasis in liver cancer. Liver international: official journal of the International Association for the Study of the Liver. 2012, 32 (7): 1064-1078.CrossRef
12.
go back to reference Meng WJ, Yan H, Zhou B, Zhang W, Kong XH, Wang R, Zhan L, Li Y, Zhou ZG, Sun XF: Correlation of SATB1 overexpression with the progression of human rectal cancer. Int J Colorectal Dis. 2012, 27 (2): 143-150.CrossRefPubMed Meng WJ, Yan H, Zhou B, Zhang W, Kong XH, Wang R, Zhan L, Li Y, Zhou ZG, Sun XF: Correlation of SATB1 overexpression with the progression of human rectal cancer. Int J Colorectal Dis. 2012, 27 (2): 143-150.CrossRefPubMed
13.
go back to reference Klaus A, Birchmeier W: Wnt signalling and its impact on development and cancer. Nat Rev Cancer. 2008, 8 (5): 387-398.CrossRefPubMed Klaus A, Birchmeier W: Wnt signalling and its impact on development and cancer. Nat Rev Cancer. 2008, 8 (5): 387-398.CrossRefPubMed
14.
go back to reference Larsson A, Johansson ME, Wangefjord S, Gaber A, Nodin B, Kucharzewska P, Welinder C, Belting M, Eberhard J, Johnsson A, et al.: Overexpression of podocalyxin-like protein is an independent factor of poor prognosis in colorectal cancer. Br J Cancer. 2011, 105 (5): 666-672.PubMedCentralCrossRefPubMed Larsson A, Johansson ME, Wangefjord S, Gaber A, Nodin B, Kucharzewska P, Welinder C, Belting M, Eberhard J, Johnsson A, et al.: Overexpression of podocalyxin-like protein is an independent factor of poor prognosis in colorectal cancer. Br J Cancer. 2011, 105 (5): 666-672.PubMedCentralCrossRefPubMed
15.
go back to reference Wangefjord S, Manjer J, Gaber A, Nodin B, Eberhard J, Jirstrom K: Cyclin D1 expression in colorectal cancer is a favourable prognostic factor in men but not women in a prospective, population-based cohort study. Biol Sex Differ. 2011, 2 (1): 10-PubMedCentralCrossRefPubMed Wangefjord S, Manjer J, Gaber A, Nodin B, Eberhard J, Jirstrom K: Cyclin D1 expression in colorectal cancer is a favourable prognostic factor in men but not women in a prospective, population-based cohort study. Biol Sex Differ. 2011, 2 (1): 10-PubMedCentralCrossRefPubMed
16.
go back to reference Berglund G, Elmstahl S, Janzon L, Larsson SA: The malmo diet and cancer study. Design and feasibility. J Intern Med. 1993, 233 (1): 45-51.CrossRefPubMed Berglund G, Elmstahl S, Janzon L, Larsson SA: The malmo diet and cancer study. Design and feasibility. J Intern Med. 1993, 233 (1): 45-51.CrossRefPubMed
17.
go back to reference Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP: Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med. 1998, 4 (7): 844-847.CrossRefPubMed Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP: Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med. 1998, 4 (7): 844-847.CrossRefPubMed
18.
go back to reference Dahlin AM, Palmqvist R, Henriksson ML, Jacobsson M, Eklof V, Rutegard J, Oberg A, Van Guelpen BR: The role of the CpG island methylator phenotype in colorectal cancer prognosis depends on microsatellite instability screening status. Clin Cancer Res. 2010, 16 (6): 1845-1855.CrossRefPubMed Dahlin AM, Palmqvist R, Henriksson ML, Jacobsson M, Eklof V, Rutegard J, Oberg A, Van Guelpen BR: The role of the CpG island methylator phenotype in colorectal cancer prognosis depends on microsatellite instability screening status. Clin Cancer Res. 2010, 16 (6): 1845-1855.CrossRefPubMed
19.
go back to reference Jass JR, Biden KG, Cummings MC, Simms LA, Walsh M, Schoch E, Meltzer SJ, Wright C, Searle J, Young J, et al.: Characterisation of a subtype of colorectal cancer combining features of the suppressor and mild mutator pathways. J Clin Pathol. 1999, 52 (6): 455-460.PubMedCentralCrossRefPubMed Jass JR, Biden KG, Cummings MC, Simms LA, Walsh M, Schoch E, Meltzer SJ, Wright C, Searle J, Young J, et al.: Characterisation of a subtype of colorectal cancer combining features of the suppressor and mild mutator pathways. J Clin Pathol. 1999, 52 (6): 455-460.PubMedCentralCrossRefPubMed
20.
go back to reference Savarese F, Davila A, Nechanitzky R, De La Rosa-Velazquez I, Pereira CF, Engelke R, Takahashi K, Jenuwein T, Kohwi-Shigematsu T, Fisher AG, et al.: Satb1 and Satb2 regulate embryonic stem cell differentiation and nanog expression. Genes Dev. 2009, 23 (22): 2625-2638.PubMedCentralCrossRefPubMed Savarese F, Davila A, Nechanitzky R, De La Rosa-Velazquez I, Pereira CF, Engelke R, Takahashi K, Jenuwein T, Kohwi-Shigematsu T, Fisher AG, et al.: Satb1 and Satb2 regulate embryonic stem cell differentiation and nanog expression. Genes Dev. 2009, 23 (22): 2625-2638.PubMedCentralCrossRefPubMed
21.
go back to reference Lugli A, Tzankov A, Zlobec I, Terracciano LM: Differential diagnostic and functional role of the multi-marker phenotype CDX2/CK20/CK7 in colorectal cancer stratified by mismatch repair status. Mod Pathol. 2008, 21 (11): 1403-1412.CrossRefPubMed Lugli A, Tzankov A, Zlobec I, Terracciano LM: Differential diagnostic and functional role of the multi-marker phenotype CDX2/CK20/CK7 in colorectal cancer stratified by mismatch repair status. Mod Pathol. 2008, 21 (11): 1403-1412.CrossRefPubMed
22.
go back to reference Kohwi-Shigematsu T, Poterlowicz K, Ordinario E, Han HJ, Botchkarev V, Kohwi Y: Genome organizing function of SATB1 in tumor progression. Semin Cancer Biol. 2012 July 4, Epub ahead of print Kohwi-Shigematsu T, Poterlowicz K, Ordinario E, Han HJ, Botchkarev V, Kohwi Y: Genome organizing function of SATB1 in tumor progression. Semin Cancer Biol. 2012 July 4, Epub ahead of print
23.
go back to reference Iorns E, Hnatyszyn HJ, Seo P, Clarke J, Ward T, Lippman M: The role of SATB1 in breast cancer pathogenesis. J Natl Cancer Inst. 2010, 102 (16): 1284-1296.CrossRefPubMed Iorns E, Hnatyszyn HJ, Seo P, Clarke J, Ward T, Lippman M: The role of SATB1 in breast cancer pathogenesis. J Natl Cancer Inst. 2010, 102 (16): 1284-1296.CrossRefPubMed
24.
go back to reference Hanker LC, Karn T, Mavrova-Risteska L, Ruckhaberle E, Gaetje R, Holtrich U, Kaufmann M, Rody A, Wiegratz I: SATB1 gene expression and breast cancer prognosis. Breast. 2011, 20 (4): 309-313.CrossRefPubMed Hanker LC, Karn T, Mavrova-Risteska L, Ruckhaberle E, Gaetje R, Holtrich U, Kaufmann M, Rody A, Wiegratz I: SATB1 gene expression and breast cancer prognosis. Breast. 2011, 20 (4): 309-313.CrossRefPubMed
25.
26.
go back to reference Laurinavicius A, Laurinaviciene A, Ostapenko V, Dasevicius D, Jarmalaite S, Lazutka J: Immunohistochemistry profiles of breast ductal carcinoma: factor analysis of digital image analysis data. Diagn Pathol. 2012, 7: 27-PubMedCentralCrossRefPubMed Laurinavicius A, Laurinaviciene A, Ostapenko V, Dasevicius D, Jarmalaite S, Lazutka J: Immunohistochemistry profiles of breast ductal carcinoma: factor analysis of digital image analysis data. Diagn Pathol. 2012, 7: 27-PubMedCentralCrossRefPubMed
27.
go back to reference Selinger CI, Cooper WA, Al-Sohaily S, Mladenova DN, Pangon L, Kennedy CW, McCaughan BC, Stirzaker C, Kohonen-Corish MR: Loss of special AT-rich binding protein 1 expression is a marker of poor survival in lung cancer. J Thorac Oncol. 2010, 6 (7): 1179-1189.CrossRef Selinger CI, Cooper WA, Al-Sohaily S, Mladenova DN, Pangon L, Kennedy CW, McCaughan BC, Stirzaker C, Kohonen-Corish MR: Loss of special AT-rich binding protein 1 expression is a marker of poor survival in lung cancer. J Thorac Oncol. 2010, 6 (7): 1179-1189.CrossRef
Metadata
Title
Molecular correlates and prognostic significance of SATB1 expression in colorectal cancer
Authors
Björn Nodin
Henrik Johannesson
Sakarias Wangefjord
Darran P O’Connor
Kajsa Ericson Lindquist
Mathias Uhlén
Karin Jirström
Jakob Eberhard
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Diagnostic Pathology / Issue 1/2012
Electronic ISSN: 1746-1596
DOI
https://doi.org/10.1186/1746-1596-7-115

Other articles of this Issue 1/2012

Diagnostic Pathology 1/2012 Go to the issue